Micrococcus luteus vesicles for NLRP3 inflammasome suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neutrophilic pulmonary diseases, such as asthma and pneumonia, are inadequate in effectively suppressing inflammation and immune dysfunction caused by biological causative factors like bacterial-derived vesicles and LPS, particularly in the context of NLRP3 inflammasome-mediated responses.
Innovation Solution
Micrococcus luteus-derived vesicles are administered orally or intranasally to suppress the secretion of inflammatory mediators and NLRP3 protein, thereby reducing neutrophilic pulmonary inflammation and airway hyperresponsiveness by regulating immune and inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neutrophilic pulmonary diseases, then the basic inflammatory response can be addressed, but the secretion of inflammatory mediators and NLRP3 protein by pathogenic vesicles is not effectively suppressed
Solution Approach 1:
The patent utilizes beneficial bacteria-derived vesicles (from Lactobacillus and Bifidobacterium) to counteract the harmful effects of pathogenic vesicles. These beneficial vesicles carry anti-inflammatory molecules that suppress the secretion of inflammatory mediators and NLRP3 protein by pathogenic bacteria, converting a potentially harmful interaction into a beneficial therapeutic effect.
Solution Approach 2:
The patent introduces beneficial bacteria-derived vesicles as intermediary substances that mediate the interaction between pathogenic vesicles and the host immune system. These vesicles act as carriers of anti-inflammatory molecules, facilitating the suppression of harmful inflammatory responses without direct contact between pathogenic and host cells.
2Adaptability or versatility
If bacteria-derived vesicles are used to exchange information with host cells, then immune regulation can be achieved, but the vesicles must pass through the mucosal barrier which blocks particles of 200 nm or more
Solution Approach 1:
The patent changes the size parameter of the vesicles by selecting beneficial bacteria that produce vesicles smaller than 200 nm. This parameter change enables the vesicles to pass through the mucosal barrier while maintaining their ability to regulate immune responses. The patent specifically mentions that the vesicles have a size of 200 nanometers or less, allowing them to penetrate the mucosal barrier.
3Productivity
If pathogenic gram-negative bacteria vesicles are absorbed into vascular endothelial cells, then systemic inflammatory response and blood coagulation are promoted, but this leads to severe pulmonary disease
Solution Approach 1:
The patent applies preliminary anti-action by introducing beneficial bacteria-derived vesicles that preemptively suppress the secretion of inflammatory mediators and NLRP3 protein before pathogenic vesicles can induce severe pulmonary disease. The beneficial vesicles actively counteract the harmful effects of pathogenic vesicles, preventing the development of severe inflammation and tissue damage.
Data Source
AI summary
Provided is a method for ameliorating, preventing or treating neutrophilic pulmonary diseases, by administering a composition comprising Micrococcus luteus-derived vesicles as an active ingredient, the composition being capable of effectively treating a neutrophilic pulmonary disease mediated by a nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome (NLRP3 inflammasome).